Upstream treatment of acute coronary syndrome in the ED - 06/08/11
, Michael Kontos, MD b, Deborah B. Diercks, MD aAbstract |
Rapid risk stratification, selection of downstream management options, and institution of initial pharmacotherapy are essential to ensure that patients admitted to the emergency department with acute coronary syndromes receive optimal care. A broad range of antiplatelet and antithrombotic medications is available that permits tailoring of initial pharmacotherapy to each patient's risk status. In the urgent setting, thienopyridines (clopidogrel and prasugrel) carry limitations including response variability and increased risk for bleeding in patients requiring subsequent coronary artery bypass graft surgery. Glycoprotein IIb-IIIa receptor inhibitors, although they are highly effective in preventing ischemic events, must be used with care to reduce bleeding risk. Bivalirudin, a relatively new direct thrombin inhibitor, represents another upstream option but is costly and does not have approval for this indication. Simplified institutional management paradigms can streamline the process of selecting appropriate pharmacotherapy and aid in care delivery that will optimize patient outcomes.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | Editorial assistance for this article was provided by Rina Kleege, MS. This assistance was funded by Schering Corp, a division of Merck and Co., Whitehouse Station, NJ. |
Vol 29 - N° 4
P. 446-456 - mai 2011 Retour au numéro
Article précédent
- Can clinical prediction rules used in acute pediatric ankle and midfoot injuries be applied to an adult population?
- Kimberly R. Smith, Charles K. Brown, Kori L. Brewer
- Snakebite: use of antivenom in a pregnant woman
- Hsing-Lin Lin, Tsung-Ying Lin, Wei-Che Lee
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?